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The phrase "the demography of Alzheimer's disease" may be
the best litmus test to distinguish demographers from
epidemiologists.

A typical reaction to this phrase from a

demographer is "why Alzheimer's disease?"

A typical reaction

from an epidemiologist is "why demography?"

It is always tricky

to describe the exact boundaries that separate two similar
disciplines and this is especially true of the difference between
demographic and epidemiologic approaches to mortality and health.
What made Preston's work on smoking and mortality demography
rather than epidemiology?

What differentiates a demographer's or

a sociologist's work on factors affecting residence in nursing
homes from an epidemiologist's work on the same topic?
The demographer's question, "why Alzheimer's disease," is
relatively simple to answer.

If Alzheimer’s disease (AD) is as

important a cause of death and institutionalization as is often
claimed, we cannot forecast mortality or residence patterns
without considering the possible effects of new treatments or
therapies for AD.

It is often claimed that Alzheimer's disease

is the fourth leading cause of death in the U.S.

If there is any

truth to this statement, we should be as interested in
Alzheimer's disease as we are in cancer, heart disease, AIDS or
violence.

We should also be as interested in the potential

impact of slowing or stopping the progression of Alzheimer's
disease as we are in following trends in smoking or in the sexual
practices that spread AIDS in the U.S. or in Africa.

Similarly,

there is research that suggests that as much as 40% of persons
entering nursing homes have Alzheimer's disease (Rovner, 1993).
If we are interested in understanding and projecting residence
patterns of the elderly, we would ignore developments in the
treatment or management of Alzheimer's disease at our peril.
The epidemiologist's question, "why demography," is not as
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easy to answer in a few sentences.

I think that asking questions

that demographers are apt to ask leads to different models for
studying and describing the progression of Alzheimer's disease.
In particular, demographers’ interest in projecting population
size, mortality rates, and residence patterns leads to different
ways of conceptualizing the role of AD and different methods for
studying it.
Predicting future advances against disease is a perilous
business.

For example, there are wildly varying projections of

the likelihood breakthroughs in preventing or treating cancer or
AIDS.

Often disease processes turn out to be more complicated

than expected, optimistic claims for new discoveries turn out to
be unwarranted, and progress with rare forms of the disease don’t
prove to be effective against more common forms.

On the other

hand, breakthroughs often come from unexpected directions and are
hard to foresee.
Although it is difficult to predict when new therapies for
AD will be available, how effective they will be and what
proportion of the population will actually benefit, several
things are clear.

First, there is a great deal of money being

spent to find treatments for AD and a number of different avenues
of research are proceeding simultaneously.

Second, one drug

(Cognex) currently provides short term improvement for some
patients.

It is very likely that better drugs will be discovered

to slow the progress of the disease or at least slow its effects
on cognitive functioning.

It is less likely that there will soon

be drugs to prevent the disease, and very little likelihood that
a cure will be discovered that can substantially reverse the
effects of the disease.

Third, it is still not clear whether AD

is the result of a single causal mechanism or whether there are
really several disease processes that can lead to the same
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symptoms.

For example, AD may be caused by an increase in the

particular forms of amyloid produced by the body or it could be
caused by a failure of the body to break down unwanted forms.
Either could lead to accumulations that cause the plaques and
tangles that are the defining characteristic of AD.
Alternatively, the accumulation of plaques and tangles could
result from rather than cause cell death.

Since there may be

several mechanisms causing the disease, it is not clear that one
drug would be equally effective against all forms of the disease.
Given these facts, demographic projections with 10 to 20
year time horizons should at least include considerations of what
will happen if the rate of progression of AD is slowed in a
sizeable proportion of cases.

Optimistic expectations for the

next 10 years seem to involve reducing the rate of progression by
half, at least during the early and middle stages of the disease.
The first section below reviews studies of the prevalence of
Alzheimer’s disease. This is not meant to be a thorough
literature review of these topics.

Instead it is meant as a

summary of the findings of the most prominent studies and the
conclusions from previous literature reviews.

A simulation of

incidence and prevalence is used to test the importance of timing
of diagnosis (or minimal severity for diagnosis) on prevalence.
This is a preliminary model with ignores heterogeneity in the
disease and relies on data collected from several different
populations.

The next part of the paper explores the claim that

Alzheimer’s disease is the fourth leading cause of death in the
U.S.

This widely quoted claim is based on one paragraph in a

editorial published in 1976 (Katzman).

The second section uses

results from two community studies to test this claim.

The third

section uses the preliminary simulation derived previously to
test this claim. The evidence on these topics is not as strong as
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we would like.

However, it is clear that Alzheimer's disease is

very common among the elderly and is at least an important
underlying cause of death and institutionalization.

The fourth

section carries out a simple simulation to illustrate what might
happen to mortality if the rate of progression of AD were slowed
substantially.

The Prevalence and Incidence of Alzheimer’s Disease
Many surveys have estimated the prevalence of senility,
dementia or Alzheimer's disease (AD) in communities.

These

surveys have used different screening tests and varying criteria
for clinical diagnoses.

The variation in the methods used in

these surveys reflect changes over the past four decades in our
understanding of dementia.

Forty years ago, Alzheimer’s disease

was considered to be a minor cause of dementia.

Today, it is

estimated to be responsible for about 60 to 65% of all dementia.
During the last ten years there have been many changes in the
diagnostic criteria, particularly in the criteria used to rule
out small strokes (i.e., multi-infarct or vascular dementias) as
the cause of dementia.
The best surveys are based on active surveillance.

This

involves canvasing the population (preferably both the communitydwelling and institutionalized populations) with a relatively
simple screening test for dementia then performing clinical
evaluations of those with a low score on the screening test.

In

addition, it is necessary to have clinical evaluations of a
sample of those who did well on the screening test to estimate
the sensitivity of the screen.

However, many of the surveys

published in the past 15 years have relied on cases identified
through routine medical examinations (i.e., on passive
surveillance).

The results of the two types of studies are often
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very different.

For example, some long term studies based on

passive surveillance suggest that the prevalence of AD has
increased over the past fifteen years.

Since it is most likely

that passive surveillance studies might be biased by under
diagnosis of AD, it is preferable to limit reviews of prevalence
to studies based on active surveillance.
Figure I presents age-specific prevalence rates from several
major surveys or reviews of surveys.

One of the best reviews of

the prevalence of dementia is that by Jorm, et al. (1987).

They

reviewed studies of the prevalence of dementia published between
1945 and 1985.

Eighteen studies provided separate figures for

Alzheimer’s disease.

They found a consistent exponential

increase in the prevalence of dementia by age with the rate
doubling between 5-year age groups.

Specifically, they estimate

that the prevalence of dementia increases from 1.4% at ages 65-69
to 38.6% at ages 90-95.

They found that the prevalence of AD

doubles with every 4.5 year increase in age, but they do not
present age-specific estimates for AD.
A review of prevalence studies in Europe was carried out as
part of the European Community Concerted Action Epidemiology and
Prevention of Dementia (EURODEM) project (Rocca, 1991).

The

average prevalence rates for six European studies shows AD
increasing from a prevalence of 0.3% at ages 60-69 to 10.8% at
ages 80-89.
The most frequently quoted study of the prevalence of AD in
the U.S. was carried out in East Boston, Massachusetts.

This

study covered all noninstitutionalized individuals living in a
defined community.
rates for AD.

This study produced very high prevalence

They estimated the prevalence rate over age 65 at

10.3% compared to only 3.1% in the European studies.

Although a

few other studies have found similar high estimates (e.g.,
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Pfeffer, 1987, for individuals living in owner-occupied houses in
a retirement community in southern California), it is quite
possible that the East Boston results overstate the prevalence of
AD in the U.S. as a whole.
The Canadian Study of Health and Aging (CSHA) is a more
recent study designed to estimate the prevalence of dementia and
Alzheimer's disease in community and institutional-dwelling
Canadians (CSHA, 1994, Ebly, 1994).

The large sample (9,008

community-dwelling and 1,255 institution-dwelling) was selected
using computerized records of the provincial health insurance
plan (or other records in Ontario).

The population over age 85

was oversampled to improve the reliability of the estimates at
the oldest ages.

Because of its size, the quality of the

sampling frame, the coverage of both community and
institutionalized population, and the similarity of Canadian
demography to that of the U.S., the Canadian survey may provide
the best estimates of the proportion of the U.S. white population
that meet the most recent criteria for clinically diagnosed
Alzheimer's disease.

The CSHA produced estimates of the

prevalence of AD that are similar to the results of a number of
European studies.

However, the CSHA estimates are much lower

than those produced for East Boston.

The estimate for those over

age 65 is 5.1% which falls between the estimates from the
European (3.1) and the East Boston (10.3%) studies.

Over age 85,

the CSHA gives a prevalence of 21.5% (95% C.I: 19.5-23.8)
compared to 47.8 (37.0-63.2) for East Boston.
There are numerous potential sources of differences between
various estimates of prevalence.

These include real differences

among populations, differences in the accuracy of disease
histories given by informants, and differences in the sensitivity
and specificity of screening tests in different populations.
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The simulations of the incidence and prevalence of AD are
useful for investigating the potential importance of another
sources of differences between studies: the use of different
levels of severity as the cut-point for diagnosing cases.

At

present, we do not diagnose Alzheimer's disease until the effects
of cognitive impairment are apparent in daily life (although
rarely used biopsy methods are available).

However, many

researchers are examining potential early markers for the
disease.

A recent example is research suggesting that

hypersensitivity of the eye to tropicamide might serve this
purpose (Scinto, 1994).

With different clinical criteria used in

various surveys and with the potential for a predictive test, the
measured prevalence of Alzheimer's might change substantially
over time as the definition of diagnosable AD changes.

This

could cause confusion of the sort caused by changes in the
definition of AIDS and the development of serum tests for HIV
positivity.

It is therefore useful to examine the extent to

which estimates of prevalence might be affected by changes in the
duration at which diagnoses can be made.
To examine these issues, we need a model that simulates the
relationship between hypothesized age-specific incidence rates,
duration-specific mortality rates for cases and non-cases, the
timing of diagnosis and observed prevalence.

Figure II presents

the results of a simple model to fit the observed prevalence by
age reported by the CSHA.

The model uses mortality rates for

U.S. whites from the life table for 1985 (the most recent life
table for which I had mortality rates for five-year age groups
over age 85).

The incidence rate is assumed to increase at a

constant rate by age.

This assumption reflects the observation

that prevalence increases exponentially across age (Jorm, 1987).
Modeling the relationship between the observed prevalence
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rates and the generally unobserved incidence rates requires
survival rates for cases and non-cases.

It is clear that the

relative survival rate of AD patients relative to controls
declines with increasing severity or duration of disease.
However, there are few studies that provide estimates of the
survival of patients with AD by duration of disease.

Most

studies start with the assumption that survival is a function of
age and then ask whether some measure of severity or duration has
an additional effect.

Although most studies find a clear effect

of severity or duration (as we would expect in a disease
characterized by persistent deterioration), few studies provide
enough detail on the effects of age or duration to be useful for
modeling.
An exception is the study by Mölsä, et al (1986), which
provides six-year survival rates for patients identified in a
survey of community-dwelling individuals in Finland.

They

provide survival rates for three levels of initial severity
(moderately demented, markedly demented, and severely demented).
Unfortunately, the data are only presented graphically and
relative to the survival of non-demented individuals.
presents estimates read off of their graphs.

Table Ia

Table Ib presents

estimates of the one-year survival rates relative to nondemented
individuals.

The values for the three groups are matched with

durations of disease which lead to maximum agreement among the
three groups for the same durations.

Since the actual onset of

disease cannot be observed (and its definition is not clear at
this time), I have set the diagnosis of the moderately demented
at duration 3 years.

When aligned as they are in Table Ib, the

survival rates for the three groups are very consistent.

This

allows us to estimate the schedule of survival relative to
nondemented individuals by duration of disease shown in the last
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column of Table Ib.
The simulation model starts with estimated incidence rates.
Non-cases are projected using age-specific mortality rates for
non-cases estimated by the model (see below).

Cases are

projected forward by age and duration using the age-specific
mortality rates for non-cases combined with duration-specific
relative survival rates for AD cases relative to non-cases.
Since the relative risk data compare cases and non-cases and we
only have overall mortality rates (for the U.S. in 1985), we need
to calculate the mortality rate for non-cases.
this includes the prevalence rate.

The formula for

Therefore, the computer

program needs to iterate a few times so that the prevalence rates
and the mortality rates for cases and non-cases are consistent
with the assumed overall mortality rates and relative risks.

At

each iteration the relative risk associated with AD at each age
is calculated from the distribution of cases by duration (derived
from the incidence rates and survival rates) and the durationspecific relative mortality rates.
This leads to a model of the prevalence of AD which involves
two parameters: the proportionate increase in incidence over age,
and the incidence rate at one given age (arbitrarily chosen as
age 87).

I have identified the values of these two parameters

which minimize the mean squared error fit to the data from the
CSHA.

This model fits the CSHA data extremely well (Figure II).

The root mean squared error for the five age-specific prevalence
estimates (measured in percent) is only 1.21 which is well within
the standard errors for the estimates from the CSHA.

The

parameters suggest that the incidence rate increases by about
13.2 percent per year of age (equivalent to a continuous rate of
change of 12.4%)

which implies that the incidence rate doubles

every 5.6 years.

The estimated incidence rates at ages 77 and 82
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(1.7% and 3.2%) are similar to the incidence rates for dementia
observed in the Bronx Aging Study (Aronson, 1991), 1.3% at 75-79
and 3.5% at ages 80-84.
Figure II also shows estimates from the simulation of the
proportion of the population that is at various stages of
Alzheimer’s disease.

I have rather artificially set at three

years the point at which a patient could clearly be diagnosed
with AD using the NINCDS/ADRDA criteria used in the CSHA.

If we

could diagnoses AD three years earlier (through predictive
changes in cognitive tests, or biological markers), the estimated
prevalence rates (labeled “earlier dx.” in Figure II) would be
substantially higher.

On the other hand, studies that applied

more severe symptoms for diagnosis might not diagnose cases for
an additional three years (on average).

This would lead to the

prevalence of what might be termed “moderate and severe” AD.
Moderate cases (those at 3-5 years after early diagnosis) would
generally require substantial assistance with everyday
functioning.

Even more stringent criteria might include only

patients about 6 years after they because diagnosable according
to the NINCDS/ADRDA criteria (9 years after incidence).
would approximate the prevalence of “severe” cases.
patients would require extensive care.

This

These

It is at this stage of

the disease that many families decide to place a patient in a
nursing home.
The simulation suggests that if we could diagnose AD on
average three years earlier than the CSHA study, the prevalence
at age 85 would increase from 13.6% to 23.9%.

If we used a more

strict criteria and diagnosed AD on average three years later
than the CSHA, prevalence would drop to 6.8 at age 85.

At age

99, the three criteria would lead to estimates of 80%, 58% and
35%.

Clearly, the estimated prevalence of AD is very sensitive
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to the diagnosis criteria or the stage of the disease that is
relevant for a given purpose.

Despite the wide range of

estimates, the estimates from the study in East Boston are still
about 35% higher than the estimates from the simulation based on
diagnosis three years earlier than in the CSHA.

Therefore, the

high rates in East Boston are probably not merely a result of
including more mild cases of AD.
It is interesting to note that the CSHA and the simulation
model show the prevalence rate continuing to increase up to (and
beyond) age 100.

The CSHA shows the prevalence of all dementias

increasing to 85% at ages 100-106.

If the proportion due to AD

is the same as at ages 95-99, this leads to an estimated 64% with
AD over age 100.
old in Berlin.

This is in contrast to estimates for the oldest

Wernicke and Reischies (1994) found that the

estimated prevalence for ages 90-94 and 95-99 were both 42.3%.
Debates over whether the incidence of AD continues to increase at
the very oldest ages may have relevance to whether or not
dementia is a “normal” part of the aging process.
The estimated incidence rates provide an interesting
opportunity to look ahead twenty to thirty years and ask what the
demand would be for a drug that would stop the progression of AD
indefinitely.

The drug model here might be insulin for diabetics

or annual vaccinations against pneumonia or influenza.

This

projection would be important to estimating the costs of
preventing AD.

If we could diagnose AD three years earlier than

is now possible and prevent any progression of the disease in all
patients (and therefore eliminate their excess mortality), the
proportion of the population that would have to be using that
drug would be given by the cumulative incidence rates.

The

estimated incidence rates suggest that at age 75 about 11% would
require treatment.

This would increase to 33% at age 85 and 77%
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at age 95.
The simulation can also be used to examine what might happen
to mortality if the rate of progression of AD were slowed
substantially.

Since changing mortality rates will change future

age distributions, we have to switch from a population
perspective to a life cycle approach to examine this issue.
Figure III shows the survival rates used in the simulation for AD
cases relative to the rest of the population (labeled “current”).
It also shows a curve with appreciably slower progression.

This

involves taking the relative survival rates during the first 10
years and spreads them out over the first 20 years.

This is an

optimistic scenario of what might be possible in the next 10 to
15 years.

If this change in survival rates were applied to a

cohort, the prevalence of “diagnosable” AD would decline slightly
(Figure IV).

The average person-years lived with mild, moderate

or severe AD (now at 6 years after onset instead of 3) would drop
from about 1.09 years to 1.04 years.

The average person-years

lived with moderate to severe AD (now 12 years after onset
instead of 6+) would drop from 0.55 years to 0.35 years.

The

largest change is seen in the prevalence of severe AD (Figure
IV).

The average person-years lived with severe AD (now 18 years

after onset instead of 6) would drop from 0.12 years to 0.08.
The decline in the person-years lived with severe AD

might be

reflected in reduced demand for nursing home care and intensive
in-home care for severely impaired patients.
It is important to note, however, that these results are
probably very sensitive to the changes assumed in the survival
rates at various durations and the definitions of severity.
Therefore, they would depend on the effectiveness of likely
treatments at different stages of the disease as well as the
actual proportion of cases receiving the treatment at each stage.
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In addition, slowing the progression of AD for large numbers of
patients would delay the date at which services would be
required.

With a high discount rate applied to future costs,

this in itself would lower the current value of future expected
costs of AD care.

However, the only conclusion that can be drawn

from these preliminary simulations is that changes in the rate of
progression of AD might have significant effects on future demand
for nursing home placement and intensive home care services.

Alzheimer's Disease as a Cause of Death
The claim that Alzheimer's disease is the fourth leading
cause of death in the U.S. plays a central role in much of the
literature produced by the Alzheimer's Disease and Related
Disorders Association and is prominently mentioned in many
scientific articles on AD.

The original claim that AD played

such an important role in mortality appeared in an editorial in
the Archives of Neurology by Katzman (1976).

He based this

statement on survival rates observed among patients seen at
research centers.

Fox credits this claim with playing a major

role in “altering the biomedical conceptualization of Alzheimer’s
disease”(1989:71).

He also states that along with estimates of

the long-term care costs for the elderly this claim was “one of
the primary justifications for increasing federal support for
Alzheimer’s disease research” (1989:71).
Demographers are generally very skeptical about these
claims.

Alzheimer's disease is not listed among the 72 causes of

death selected for detailed tables in the U.S. vital statistics
(Kochanek, 1994).

Instead it is lumped into the "All other

Diseases" category which includes only 8% of deaths.
likely to be listed as a associated cause.

AD is more

A study by the

Centers for Disease Control (1991) found that Alzheimer's disease
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was listed as an associated cause for 26,325 deaths in 1987.
Since the classification of dementias was changing rapidly during
the 1970s and 1980s, many dementias that would now be classified
as Alzheimer's disease might have been coded as "presenile
dementia" or "senile dementia."

In fact the ICD-9 codes for

dementias do not reflect current diagnostic categories very well.
However, even if we ascribe to AD all of the deaths with "senile
and presenile dementias" listed as an associated cause, the total
is only 32,624 which would push Alzheimer's up to about eighth on
the list for 1987.

Although this at least gets AD onto the top

ten list, this is only about one-third of the number of deaths
required to push it up to number four or five.
Although vital statistics data for other low mortality
countries show similar rates for Alzheimer’s disease, it is
likely that the true significance of AD is much greater.

It is

very likely that AD is underreported on death certificates in all
countries.

This is not surprising given that AD is also grossly

underreported in patient records in nursing homes and in health
surveys.

Even death certificates for patients followed for years

in research studies are just as likely to ignore AD as to report
it.
Mortality in Community Studies

An alternative approach is

to examine data for community-based studies designed to measure
the prevalence and incidence of Alzheimer's disease.

There are

two major studies based on community screening that provide
comparisons of mortality rates by cognitive status: the East
Boston study (Evans, 1989; data for five-year age groups are
available in Beckett, 1992) and a study in Iceland (Magnusson,
1989).

The two studies provide a good contrast because they

produce very different estimates of prevalence and mortality.
noted above, the East Boston study produced estimates of the

As
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proportions with Probable AD that are higher than the rates found
in the majority of studies.

At age 80-84, the estimated

prevalence in East Boston was 25%.

In contrast, the Icelandic

study estimated that at age 81.5 only 2.8% had severe Primary
degenerative dementia.

Part of the difference between the two

rates is that the East Boston study included moderate, mild and
borderline cases whereas the Iceland study provides detailed data
only on severe cases.
The difference in the severity of cases reported in East
Boston and Iceland is reflected in differences in the reported
relative risks of mortality in the two studies.

In the East

Boston study, the relative risk of death for AD cases was 1.44
compared to that of others in the population.

The comparable

figure for the study in Iceland was 2.37 for severe AD cases.

If

we apply the prevalence estimates from the two studies and their
respective relative risks to age distribution and mortality rates
for the U.S. in 1991, the results provide a reasonable range of
estimates for the proportion of deaths in U.S. that are
attributable to AD.

The East Boston estimates suggest that

excess deaths among AD cases in the U.S. in 1991 amounted to
about 8.2% of deaths over age 60.

The estimates for Iceland

suggest that excess AD deaths amounted to 4.6% of deaths over age
60.

These correspond to 6.4% and 3.6% of deaths at all ages.

This would place AD somewhere between Cerebrovascular deaths and
Chronic Obstructive Pulmonary disease, the third and fourth
leading causes, which are responsible for 6.6% and 4.2% of all
deaths (Figure V).
It is useful to consider possible sources of bias in these
estimates.

The diagnosis of AD is not considered definite until

the presence of the plaques and tangles that cause AD has been
confirmed pathologically.

Definite diagnosis is possible through
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biopsy, but this procedure is quite rare.

Even confirmation at

autopsy is not common because autopsies are performed
infrequently.

Diagnoses based on clinical examinations of the

type performed in the CSHA are about 90% accurate.

Although the

remaining 10% may often be dementias caused by strokes, and,
therefore, falsely include some cases at high risk of death, it
is not likely that misdiagnosis could explain much of the
mortality attributed to AD.
The estimates of the significance of AD in mortality are
estimates of “attributable risk,” that is, estimates of the
excess mortality among cases of AD.

Estimates of attributable

risk rarely provide good estimates of how much mortality would
decline if a disease or risk factor were eliminated from the
population.

For example, since smokers are statistically more

likely to have other risk factors for mortality (e.g., higher
alcohol consumption, lower exercise rates), some of the excess
mortality among smokers can be attributed to other risk factors.
However, in the case of AD, the attributable risk estimates may
closely approximate the proportion of deaths attributable to AD
as an underlying cause.

The reason for this is that there are

few important other risk factors for mortality that have been
associated with increased risk of AD.

Those risk factors that

have been identified (or suggested) by previous research are
quite varied in their likely effect on mortality to other causes.
For example, although head trauma is a risk factor for AD, its
contribution is probably small enough that it would have little
affect on the mortality rate among AD cases.

In addition, it is

not likely that head trauma sustained many years earlier will
have a direct effect of risk of death.

A recent study suggests

that daily aspirin use (often recommended for reducing the risk
of heart attack) may reduce the risk of AD.

On the other hand,
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other studies suggest that smoking (which increases the risk of
heart attack) may also protect against AD.

The most common

genotype associated with increased risk of AD (the apolipoprotein
-4) is actually a low risk gene for problems associated with
cholesterol.

Overall, there is no reason to suspect that the

estimates of attributable risk associated with AD are seriously
biased upward by associations between AD and other risk factors
for mortality.

Simulation of the Role of AD in Mortality.

We can use the

simulation of the CSHA to produce another estimate of the
proportion of deaths attributable to AD.

Given the age

distribution and mortality rates for U.S. whites in 1985, the
simulation suggests that 9.6% of deaths over age 60 or 7.8% of
all deaths are excess deaths attributable to (diagnosable) AD.
If we limit the deaths attributable to AD to deaths among
moderate and severe cases (arbitrarily defined as 6 years after
incidence and 3 years after diagnosis), we estimated that 5.0% of
all deaths are attributable to AD.

This range between total

excess deaths among AD patients to excess deaths among severe
cases (5.0% to 7.8%) is slightly higher than the range between
the East Boston estimates based on mild, moderate and severe
cases and the Iceland estimates based only on severe cases (3.6%
to 6.5%).

Therefore is possible that AD could rank as high as

the third leading cause of death if we ascribed all excess deaths
among AD patients to AD as a cause of death; however, it is much
more likely AD would rank as the fourth leading cause.
The simulation also offers us the chance to examine the
potential impact of likely new treatments for AD on mortality
rates.

We can examine the effect of the changes in the relative

survival rates of AD patients shown in Figure IV and described
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above.

These changes would increase the life expectancy at age

65 by 0.31 years.

However, because of the increased severity of

cases surviving to older ages, life expectancy at age 85 would
drop by about 0.16 years.

This difference between the effect on

life expectancy at ages 65 and 85 is surprising. It probably
results from the sharp change in the relative survival rates
assumed to occur at about 20 years of duration.

If excess

mortality associated with AD were eliminated completely, life
expectancy at age 65 would increase by about 0.95 years.

Life

expectancy at age 85 would increase by almost as much, about 0.73
years.

Summary and Conclusions
Alzheimer’s disease is so prevalent among the oldest old
that demographers should be interested in it simply as a
characteristic of the population.

However, its likely role in

mortality and nursing home placement make AD an important disease
for demographic projections of population, mortality and
residence patterns.
The evidence presented here substantiates the claim that
Alzheimer’s disease is an important element in U.S. mortality.
It appears that about 4% to 7% of all deaths are attributable to
AD.

This is large enough to rank AD as the third or fourth

largest cause of death in the U.S. today.

A simulation of the

effects of slowing the progression of AD suggests that the life
expectancy at age 65 would increase by almost one-third of a year
if the rate of progression of AD were cut in half during the
first ten years after diagnosis.

Changing the rate of

progression might also change the prevalence of the disease as
well as the average person-years lived at various levels of
severity.

Cutting in half the rate of progression during the
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twenty years following onset could reduce the average personyears lived with severe AD by about one-third.

These changes

could have a substantial impact on the demand for nursing home
placement and home care services.
The simulation presented here is very crude and will need to
be refined.

In particular, it ignores heterogeneity in the

progression of Alzheimer’s disease.

Differences in rate of

progression complicate the simple relationship between severity
and duration and will require more complex modeling.

The

simulation of the possible impact of slowing progression is
simply a first attempt to begin examining what is actually a very
difficult question.

It will be important to examine in detail

the mechanisms that will underlie likely new treatments and how
they might affect mortality and cognitive functioning.

However,

the simulation presented here probably provides a good indication
of the types of conclusions that are apt to emerge from more
elaborate models.
The modeling of nursing home placement will be a much more
complex project.

One reason for this is that the timing of

institutionalization is dependent on much more than just the
severity of the impairment of cognitive function.

A minimal

model might include the effect of behavioral disturbances, the
availability of a caregiver, and some modeling of how “caregiver
burden” might be affected by slowing the rate of progression.

In

addition, slowing the rate of progression might affect the length
of stay in a nursing home (generally the time until death) as
well as the time of entry.

Another complication is that

increased availability of alternative sources of care, in
particular expanded home care services, will alter the
relationship between severity of disease and nursing home
placement.

However, the simple simulations presented here
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suggest that changes in the rate of progression might have
significant effects on the age pattern of institutionalization.
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Table Ia:

Survival Rates in Alzheimer's Disease

Relative to Nondemented Individuals
Moderate

Severe

0 1.000

1.000

1.000

1 0.930

0.910

0.890

2 0.860

0.820

0.780

3 0.790

0.730

0.670

4 0.720

0.640

0.560

5 0.650

0.550

0.450

6 0.580

0.460

0.340

Mild
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Table Ib:

One-Year Relative Survival Rates, by

Severity and Estimated Overall Rates by Duration
-----------Mild

Relative

Moderate

Px

Relative

1

Severe

Combined

lx

0

1.000

1.0000

1

1.000

1.0000

2

0.970

1.0000

3

0.959

0.9700

4 0.930

0.930

0.9300

5 0.925

0.925

0.8649

6 0.919

0.919

0.7998

7 0.911

0.910

0.911

0.7347

8 0.903

0.901

0.902

0.6691

9 0.892

0.890

0.890

0.891

0.6035

10

0.877

0.876

0.877

0.5376

11

0.859

0.859

0.859

0.4712

12

0.836

0.836

0.836

0.4049

13

0.804

0.804

0.3385

14

0.756

0.756

0.2720

15

0.600

0.2055

16

0.500

0.1233

17

0.300

0.0617

18

0.200

0.0185
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Key for Top Ranked Causes of Death from U.S. Vital Statistics,
1992:
1) Diseases of the Heart
2) Malignant Neoplasms
3) Cerebrovascular Diseases
4) Chronic Obstructive Pulmonary Diseases and Allied
Conditions
5) Accidents and Adverse Effects
6) Pneumonia and Influenza
7) Diabetes Mellitus

